Related Experiment Video
Updated: Sep 16, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry
Hayat Bazzi1, Nicholas Thuo1, Sruthi Sravanam2
1Department of Oncology, Wayne State University, Detroit, MI.
Background:
Anaplastic Lymphoma Kinase (ALK)-positive nonsmall cell lung cancer (NSCLC) primarily affects younger, nonsmoking individuals. Tyrosine kinase inhibitors (TKIs) have improved survival. While timely diagnosis and TKI initiation are critical, global data on diagnostic and treatment timelines remain scarce. This study examines key intervals from the first medical visit to diagnosis and treatment, and factors linked to delays.
Methods:
The ALK Life Study is a longitudinal observational study of ALK-positive NSCLC patients, with data collected via online surveys from September 2022 to November 2024. Patients were recruited through support groups, newsletters, and oncologist referrals. Descriptive statistics and multivariable regression identified factors influencing timelines.
Results:
A total of 1288 patients from 71 countries completed the survey. The median age at diagnosis was 52 years, 52% from the U.S., and 28% with a smoking history. For all patients, the median time from first medical visit to diagnosis (DOD) was 45 days (IQR: 16-120). For stage IIIC/IV patients, the median time from diagnosis to TKI treatment (DDT) was 30 days (IQR: 17-49). Older ages at the first visit were linked to shorter DOD, while more symptoms increased DOD. For advanced-stage patients, older age, GERD, and high blood pressure prolonged DDT, while coughing up blood and voice changes shortened it. Recent diagnosis year and residence in Canada were tied to shorter DDT.
Conclusions:
Younger age, specific comorbidities, nonspecific symptoms, and geographic factors lengthen intervals to diagnosis and treatment. Raising awareness of ALK-positive NSCLC in younger patients could improve diagnosis timelines and outcomes.
Insights
Delays in diagnosing Anaplastic Lymphoma Kinase (ALK)-positive non-small cell lung cancer (NSCLC) are influenced by patient age, symptoms, and comorbidities. Increasing awareness of ALK-positive NSCLC in younger individuals can improve diagnosis and treatment timelines.
Area of Science:
- Oncology
- Medical Diagnostics
- Pharmacotherapy
Background:
- Anaplastic Lymphoma Kinase (ALK)-positive non-small cell lung cancer (NSCLC) predominantly affects younger, non-smoking populations.
- Tyrosine kinase inhibitors (TKIs) have significantly improved survival rates for ALK-positive NSCLC patients.
- Global data on diagnostic and treatment timelines for ALK-positive NSCLC are limited, hindering timely intervention.
Purpose of the Study:
- To investigate the time intervals from initial medical consultation to diagnosis and subsequent TKI treatment in ALK-positive NSCLC patients.
- To identify demographic, clinical, and geographic factors associated with delays in diagnosis and treatment initiation.
Main Methods:
- The ALK Life Study is a longitudinal, observational study utilizing online surveys.
- Data were collected from 1288 ALK-positive NSCLC patients across 71 countries between September 2022 and November 2024.
- Descriptive statistics and multivariable regression analyses were employed to determine factors influencing diagnostic and treatment timelines.
Main Results:
- The median time from first medical visit to diagnosis (DOD) was 45 days; median time from diagnosis to TKI treatment (DDT) for advanced stages was 30 days.
- Factors associated with longer DOD included increased symptoms, while older age correlated with shorter DOD.
- For DDT, older age, GERD, and hypertension were linked to delays, whereas hemoptysis and voice changes shortened the interval. Recent diagnosis year and Canadian residency were associated with shorter DDT.
Conclusions:
- Patient age, comorbidities, symptom presentation, and geographic location significantly impact diagnosis and treatment timelines for ALK-positive NSCLC.
- Raising awareness of ALK-positive NSCLC, particularly in younger patient cohorts, is crucial for optimizing diagnostic and therapeutic pathways.
- Addressing identified delays can lead to improved clinical outcomes for individuals with ALK-positive NSCLC.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
